Announcement of Completion of Share Acquisition of
SHIGAKEN PHARM. IND. CO., LTD.
January 8, 2025
Nissha Co., Ltd.
Nissha Co., Ltd. (hereinafter “the Company”) hereby shares acquisition of SHIGAKEN PHARM. IND. CO., LTD. (hereinafter “Shigaken Pharma”) has been completed, making it a subsidiary dated as of January 8, 2025, in accordance with the “Announcement of Acquisition of Shares (Subsidiary Acquisition) of SHIGAKEN PHARM. IND. CO., LTD.” previously disclosed dated as of December 24, 2024.
Established in 1943, Shigaken Pharma is a manufacturing and marketing authorization holder of pharmaceuticals and quasi-drugs. It has carved out a strong position in the market with a contract design/development and manufacturing organization (CDMO) business model mainly for over-the-counter (OTC) drugs as cold medicines, analgesic antipyretics and others and has an extensive customer base. With this acquisition, the Company will be able to enter the pharmaceutical CDMO business. By leveraging Shigaken Pharma's production capacity and extensive customer base in combination with the Company’s managerial resources and advanced production technologies, we aim to expand the scale of our pharmaceutical business.
Established in 1943, Shigaken Pharma is a manufacturing and marketing authorization holder of pharmaceuticals and quasi-drugs. It has carved out a strong position in the market with a contract design/development and manufacturing organization (CDMO) business model mainly for over-the-counter (OTC) drugs as cold medicines, analgesic antipyretics and others and has an extensive customer base. With this acquisition, the Company will be able to enter the pharmaceutical CDMO business. By leveraging Shigaken Pharma's production capacity and extensive customer base in combination with the Company’s managerial resources and advanced production technologies, we aim to expand the scale of our pharmaceutical business.
Overview of SHIGAKEN PHARM. IND. CO., LTD.
Location | 879 Taki, Koka-cho, Koka, Shiga |
---|---|
Representative Director | Toshiyuki Yasui |
Established | 1943 |
Employees | 94 (as of end-of November 2024) |
Business Outline | Manufacturing and marketing authorization holder of pharmaceuticals |
Net sales | ¥4,877 million (fiscal year ended September 2024) |
Official website | https://www.shigaken-pharm.co.jp/ (Japanese only) |
Outlook Going Forward
The company is currently investigating the impact of this acquisition on its consolidated business results. Details will be disclosed as soon as available.
The content of the web is information at press time, may change thereafter without notice. Due to risks and uncertainties, predictions may differ from actual results. Please be forewarned.